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Minimally invasive techniques used in the evaluation and treatment of colorectal liver metastases (CRLMs) include ultrason-
ography (US), computed tomography, magnetic resonance imaging, percutaneous and operative ablation therapy, standard
laparoscopic techniques, robotic techniques, and experimental techniques of natural oriﬁce endoscopic surgery. Laparoscopic
techniques range from simple staging laparoscopy with or without laparoscopic intraoperative US, through intermediate tech-
niques including simple liver resections (LRs), to advanced techniques such as major hepatectomies. Hereins, we review minimally
invasive evaluation and treatment of CRLM, focusing on a comparison of open LR (OLR) and minimally invasive LR (MILR).
Although there are no randomized trials comparing OLR and MILR, nonrandomized data suggest that MILR compares favorably
with OLR regarding morbidity, mortality, LOS, and cost, although signiﬁcant selection bias exists. The future of MILR will likely
include expanding criteria for resectability of CRLM and should include both a patient registry and a formalized process for
surgeon training and credentialing.
1.Introduction
As the third commonest cancer in males and females and
the second commonest cause of cancer death [1], colorectal
cancer (CRC) is an important health problem in the world.
There are estimated to be 334 000 new cases of CRC in
Europe [2] and 142 570 new cases in the United States [1],
and 36% of these patients will succumb to their CRC [1].
Of all patients with CRC, approximately 65% develop dis-
tantmetastasis,andthecommonestlocation(40%)istheliv-
er [3]. The proportion of patients who presented with syn-
chronous versus metachronous colorectal liver metastases
(CRLMs) in France was equal in a recent epidemiologic st-
udy:theproportionofpatientswithsynchronousCRLMand
the 5-year rate of metachronous CRLM were both 14% [4].
Unfortunately, only 25% of patients with CRLM are amena-
ble to curative-intent treatment [3, 5–7].
Sincetheﬁrstreportofalaparoscopicliverresection(LR)
in1992(forCRLM)[8,9],theﬁeldofminimallyinvasiveliv-
er resection (MILR) has seen tremendous advances, parallel-
ing those of open liver resection (OLR), with increasing safe-
ty and eﬃcacy. Although most early MILRs were for benign
disease, the ﬁrst report notwithstanding, an increasing vol-
umeofnonrandomizeddatasuggestsnooncologicdisadvan-
tage to performing MILR compared to OLR.
2.MinimallyInvasiveEvaluation
Transabdominal US is a widely available, inexpensive, and
noninvasive technique of evaluating for CRLM but, com-
pared with other modalities, has the lowest sensitivity and
negative predictive value [10], excepting contrast-enhanced
ultrasound, which by some studies is as sensitive as CT [11]
but which is not available in the United States. Consequently,
CT and MRI are among the most commonly employed mo-
dalities used to evaluate the liver for CRLM. A recent meta-
analysis of diagnostic imaging of CRLM, evaluating 39 arti-
cles (3391 patients), found MRI to be the optimal ﬁrst-line
modality, with a per-patient sensitivity of 88% [12].2 International Journal of Surgical Oncology
While early (1990s) studies showed staging laparoscopy
(SL) to be superior to preoperative imaging in detecting un-
resectable or extrahepatic disease, thereby sparing as many as
34% of patients a laparotomy [13], when combined with
intraoperative ultrasound (IOUS), even in an era of mark-
edly improved axial imaging (2000s), SL was able to detect
unresectablediseaseandpotentiallypreventunnecessarylap-
arotomiesin10–25%ofpatientswithprimaryandsecondary
hepatic malignancies [14–16].
Increasing quality in preoperative axial imaging technol-
ogy, however, has challenged the use of laparoscopic IOUS.
In a prospective study of 194 patients undergoing LR for
CRLMpublishedin2008,Tamandletal.compareddatafrom
preoperative imaging using multidetector CT (MDCT) and
MRI to intraoperative ﬁndings using IOUS and bimanual
palpation and found that IOUS provided useful information
regarding additional CRLM in only 2.6% of patients [17].
Other groups, however, have consistently found that 10% of
additional small tumors that were missed by axial imaging
maybedetected[18,19]andthepreoperativetreatmentplan
ma ychangeinnearlyhalfofcases[15]whenacompleteeval-
uation is performed, including exposure of the entire surface
of the liver and porta hepatis, an IOUS scan of all 8 liver seg-
ments, porta hepatis and the paraceliac nodal bed, and a
thorough evaluation of the entire peritoneal cavity to detect
extrahepatic metastases. Whether done laparoscopically or
open, a complete US evaluation of the liver should include
four steps: (1) an identiﬁcation of intrahepatic vascular anat-
omy, (2) identiﬁcation and characterization of known le-
sions, (3) a search for previously unrecognized lesions, and
(4) the planning of a treatment strategy, which may include
resection, ablation, or both. Intrahepatic tumors are evalu-
ated for size, number, location, relationship to biliary and
vascular structures, and echogenicity (most CRLMs are hy-
poechoic (42%) or isoechoic (43%), while a minority (15%)
are hyperechoic [18]). Echogenicity should be noted because
it has been shown to correlate with long-term survival: in a
prospectiveevaluationof147patientsatJohnsHopkinsHos-
pital, the 5-year survival for patients with hypo-, iso-, and
hyperechoic CRLM was 14%, 37%, and 46%, respectively
[20].
3.MinimallyInvasiveTreatment Techniques
3.1. Ablative Techniques. Standard ablative techniques in-
clude both chemical and thermal ablation and are increas-
ingly used, both in isolation for patients with unresectable
CRLM and in combination with LR. Chemical ablation with
ethanol or acetic acid has been performed for CRLM but is
less eﬀective for CRLM than for hepatocellular carcinoma
[21–23]. Thermal ablation is therefore the preferred treat-
ment for CRLM not amenable to surgical resection. Thermal
ablationincludesradiofrequencyablation(RFA),microwave,
laser, and cryoablation. In these techniques, focal heating or
freezing of tumor cells causes local tumor destruction while
preserving surrounding hepatic parenchyma. An emerging
and still poorly studied technique is the nonthermal, non-
chemical technique of electrical ablation using irreversible
electroporation.
Although operative ablation of CRLM is often done in
combination with both MILR and OLR, percutaneous ab-
lation of CRLM is appropriate in cases in which no resec-
tion is planned and oﬀers an attractive minimally invasive
treatment option for such patients. However administered,
RFA is relatively safe and less invasive than formal hepatic
resection, but several notable complications may occur, in-
cluding hepatic failure, hydrothorax, intraperitoneal bleed-
ing, hepatic abscess, bile duct leaks, and tumor seeding [24–
28]. The reported procedure-related morbidity ranges from
2% to 12% and the mortality rate from 0% to 4.3% [24,
26–29]. Many of these reports, however, include a variety
of approaches, including percutaneous, laparoscopic, and
open, and include more cases of HCC than CRLM [24, 27–
29]. Given the frequent association of HCC with cirrhosis,
complications such as bleeding, liver failure, and death may
be more common following ablation of HCC than CRLM
[24, 27]. In a recent report of 100 patients undergoing RFA
for CRLM, there was no procedure-related morality and the
major complication rate was 8% [30]. Another study of
100 patients undergoing RFA (146 treatments) for CRLM
revealedamajorcomplicationrateof4.8%,including1death
from liver failure [31]. Gillams and Lees similarly found a
major complication rate of 4.0% in a series of 167 patients
undergoing RFA for CRLM [32].
Microwave ablation (MWA) is an emerging technology
that can also be performed open, percutaneously, or laparo-
scopically. Like with RFA, however, no randomized trials
support its use over other techniques. The primary theoreti-
cal advantages of MWA are the ability to ablate larger lesions
and to do so faster. These advantages likely derive from the
fact that MWA, unlike RFA, does not rely on electric cur-
rent and so is not impeded by tissue desiccation and char-
ring, both of which decrease electrical conductivity. In addi-
tion, there is no so-called “heat sink” eﬀect, or heat loss from
adjacentbloodvessels,whichinthecaseofRFAdecreasesthe
eﬀectiveness and increases the time required for ablation.
Most reported experiences have demonstrated safe and ef-
fective MWA, with complications and local recurrence rates
comparable to RFA [33–35]. Theoretical disadvantages in-
clude the inadvertent injury to adjacent structures and the
risk of such collateral damage makes tumor location impor-
tant in the decision of which modality (e.g., RFA versus
MWA) and route (e.g., open versus laparoscopic) to choose.
Ablation of dome lesions or left lateral segment lesions, for
instance, could expose the diaphragm and heart to thermal
injury and serious morbidity, and such lesion may be bet-
ter treated with an open or laparoscopic as opposed to per-
cutaneous technique.
Cryoablation can similarly be performed via percutane-
ous or open approaches. It oﬀers many of the same bene-
ﬁ t so fR F Aa n dM W A ,s u c ha sp r e s e r v a t i o no fl i v e rp a r e n -
chyma,butatapotentiallyincreasedcost,giventhatthecom-
plication rates may be higher compared with RFA: mor-
bidity 10–40% and mortality 0–5% [36]. Complications
include hepatic/iceball fracture (19%), hemorrhage (3.7%),International Journal of Surgical Oncology 3
coagulopathy(3.8%),biliaryﬁstula(2.9%),andorganfailure
[36]. Furthermore, animal models have demonstrated that
there is a more severe systemic response following cryother-
apy than following RFA [37].
Irreversible electroporation (IRE) is an emerging, non-
thermal, nonchemical technique that uses electrical current
todestroycells.Itsreversiblecounterpart,reversibleelectrop-
oration, is a common laboratory technique that has been
employed for decades to transiently render cells widely per-
meable to allow entry of large molecules such as drugs and
genesbyapplying anelectricalﬁeldtocellsthatareotherwise
not permeable to the molecules of interest [38]. IRE, pre-
viously viewed as an undesireable upper limit of reversible
electroporation because it rendered the cells permanently
permeable and therefore nonviable, is now used clinically as
a form of nonthermal ablation. While supported by animal
models [39–41] and available commercially for use in pa-
tients, IRE has not been well studied in patients. It does
have the theoretical advantages, however, of being very fast
(micro- to milliseconds), preserving connective tissue archi-
tecture thereby allowing ablation close to vital structures in
the liver hilum for example, and unlike thermal techniques it
is not likely aﬀected by blood ﬂow [38]. As with many new
techniques, all cases of IRE performed should be registered
t od o c u m e n tt h er o l ea n ds a f e t yo fI R E ,a sw e l la st oi d e n t i f y
important questions for study in clinical trials, and indeed
such a registry is underway at the University of Louisville
[42].
3.2. Ablation and Resection.
(1) Surgical resection is the standard of care for CRLM,
b u tR F Ah a sp r o d u c e dc o m p a ra b l eo u t c o m e sf o rl i m -
ited disease, with some important caveats. Although
RFA has demonstrated 5-year survival rates as high
as 30% in some studies [31, 32] and numerous other
studies have attempted to compare resection and
ablation [43–47], recent analyses using propensity
scoremethodology[48,49]haveshownthatcompar-
ison of survival rates following RFA and resection is
not reliable, due to major diﬀerences in clinicopatho-
logic characteristics, RFA technologies and expertise,
and analysis of margin status (namely, lack of patho-
logic analysis after RFA since no specimen is avail-
able). Until randomized controlled trials comparing
RFA and surgical resection are available, the question
of their comparability will likely remain unanswered
[50]. In a recent systematic review performed by
the American Society of Clinical Oncology in 2009
regarding RFA for CRLM [51], over 400 published
articles were reviewed, 46 identiﬁed as having over
10 patients with adequate followup and perioperative
data to analyze. There was a wide variability in the
reported 5-year survival (14–55%) and local tumor
recurrence (3.6–60%) [51].
While comparisons to resection may be unreliable and
largely unrevealing, comparisons within RFA series have
been more fruitful. For instance, it has become clear that
increasing CRLM size—especially size >3cm—is directly
proportional to shorter survival and higher rates of recur-
rence [52–54] .W h i l es o m es t u d i e sh a v ef o u n dt h i st ob et r u e
regardless of the approach (open, laparoscopic, or percu-
taneous) [53], other studies have found worse local tumor
recurrence and disease-free survival in percutaneously treat-
ed patients compared with open cases [55]. Prognostic fac-
tors that contribute to overall outcome include node status
of the primary CRC resection, synchronous versus metach-
ronous disease, number and size of lesions, margin status of
resected hepatic lesions, CEA levels, the presence of extra-
hepatic disease, satellite lesions and systemic treatment [51].
RFAisanoperator-dependentprocedure,whetheropen,lap-
aroscopic, or percutaneous, and requires careful technique
and patient selection to achieve optimal outcomes.
3.3. Laparoscopic LR, Hand-Assisted Laparoscopic Surgery
(HALS), and Hybrid Approaches. Although initial laparo-
scopic liver surgery was typically limited to wedge resections
of benign lesions that were easily accessible [8, 9, 56], more
advanced liver resections are now performed laparoscopi-
cally, including totally laparoscopic right, left, and central
hepatectomies, extended right and left hepatectomies, and
posterosuperior resections [57–63].
Many surgeons wishing to perform MILR begin a step-
wise process of beginning with easy minor resections (Figure
1), later using a hand port [64–67]o rh y b r i dt e c h n i q u e[ 68]
for complex resections before ﬁnally attempting totally lap-
aroscopic major resections. However, even when the dissec-
tion and transection of the liver is totally laparoscopic in
cases of extended hepatectomies, the specimen is large and
requires an incision for removal [58, 59]. This incision is
o f t e na sl o n ga st h a tr e q u i r e df o rah a n dp o r t ,w h i c hi so n e
reason that many have advocated for maintaining—and in
some cases returning to—a hand-assisted as opposed to a
totally laparoscopic approach [66, 67]. The main advantages
of HALS are tactile feedback, including ability to palpate the
liver, tumor, and nodes, facile liver mobilization and retrac-
tion, quick and easy hemostasis with digital compression in
casesofunexpectedhemorrhage,andthemultipleadditional
uses of the hand-port incision, including placement of
additional instruments and removal of the specimen.
The hybrid technique, combining the relatively basic lap-
aroscopic skills of liver mobilization with the more advanced
but open dissection of the liver hilum and transection of
the liver parenchyma through a minilaparotomy, the small
size of which is made possible by the laparoscopic mobili-
zation [68], is another eﬀort to shorten the learning curve
(see below) associated with MILR, thereby increasing the
numbersofpatientswhomaybeneﬁtfromMILR.Thehybrid
approach, like the HALS approach, is meant to combine the
advantages of laparoscopic surgery (decreased postoperative
pain and improved cosmesis, largely due to the avoidance of
a subcostal incision) with the safety, ease, and accessibility
provided in open procedures.
3.4. Robotic Liver Resection. Robotic surgery overcomes
certain limitations encountered with the laparoscopic tech-
nique, such as 2-dimensional images and linear instruments,4 International Journal of Surgical Oncology
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Figure 1: CRLMs accessible for straightforward MILR. (a) A
hypodense CRLM in segments 2/3; (b) A hypodense CRLM in
segment 6.
and oﬀers clear advantages such as 3-dimensional imaging,
tremor ﬁltration, higher magniﬁcation, and articulating in-
struments with seven degrees of freedom. These advantages
allow improved visualization and improved surgeon dexter-
ity for ﬁne movements, especially intracorporeal suturing.
Disadvantages inherent in the complex robotic technol-
ogy include signiﬁcant expense of the acquisition and main-
tenance of a robotic system, longer operating times, a sig-
niﬁcant learning curve to becoming proﬁcient with the set-
up and utilization of the instruments, a loss of tactile feed-
back, and the requirement of a skilled assistant, as both the
assistant and console surgeon perform integral parts of the
hepatic transection [69, 70].
The worldwide experience with robotic LR is somewhat
limited with approximately 100 reported cases, but the ap-
proach appears to be safe in experienced hands [71–74]. The
largestseriesfromGiulianottietal.[71]reported70patients,
66ofwhomunderwentsuccessfulroboticresectionand16of
whom had colorectal metastases (4 minor resections and 12
major).Theaveragesurgicalmarginforcolorectalmetastases
was 25mm and the overall morbidity was 21% with a mor-
tality of 0% and a median length of stay (LOS) of 7 days [71].
Two smaller series of robotic hepatectomies for CRLM and
other diagnoses Berber et al. [73]a n dJ ie ta l .[ 74]a p p e a r
to have similar outcomes with 9 patients and 13 patients,
respectively. The margins were not compromised in either
group, with morbidity ranging from 7.8 to 11%, with no
mortality [73, 74]. Even very complex cases, such as single-
stage, combined liver and colon resection for synchronous
CRLM, have been performed with robotassisted laparoscopy
[75].
3.5. Laparoscopic Placement of Hepatic Artery Infusion (HAI)
Catheter. Given that a number of studies suggest that re-
gional (as opposed to systemic) chemotherapy may improve
the response CRLM and possibly improve survival in pa-
tients with resectable and unresectable CRLM [76–80], the
principle rational for HAI catheter is that CRLMs derive
80% to 100% of their blood supply from the hepatic ar-
tery, as opposed to the portal vein [81]. This allows for a
high concentration of chemotherapeutic agents to be de-
livered directly into the tumors, with maximal eﬀect on the
metastatic lesion, minimal parenchymal and systemic toxi-
city, and minimal loss of activity due to the ﬁrst-pass he-
patic extraction [82]. The laparoscopic approach provides a
minimally invasive way to obtain such an access to the he-
patic artery by avoiding the morbidity and mortality associ-
ated with standard laparotomy procedures. Multiple studies
have shown that laparoscopic HAC placement is a feasible
and safe procedure [83–85].
3.6. Transarterial Embolization, Chemoembolization, and Ra-
dioembolization. Hepaticarteryinfusionisonlyoneofsever-
al ways to deliver therapies transarterially to the liver, thereby
minimizing systemic toxicities. Other transarterial thera-
pies include transarterial embolization (TAE), transarterial
chemoembolization (TACE), and intra-arterial radiotherapy
(IART), among others, all of which share with HAI the
advantages associated with delivery of therapy via the he-
patic arterial system. There is not an overabundance of high-
quality data supporting either TAE or TACE over the other,
and, when compared, both have produced median survival
results of 8–12 months [86, 87]. Nevertheless, since TACE
provides two therapies in one—both an ischemic and a toxic
insult to the CRLM—it is generally preferred. Albert et al.
recently evaluated 121 patients undergoing 245 TACE treat-
ments and found a 27-month overall median survival using
cisplatin, doxorubicin, mitomycin C, ethiodized oil, and po-
lyvinyl alcohol particles [88] .N e i t h e rT A C En o rT A Ei sa s
well studied as the treatment of CRLM compared with he-
patocellular carcinoma, and more data are needed to deﬁne
this role.
Similarly,IARTistheembolizationofaradiation-emitter
into the hepatic arteries feeding the CRLM. The only FDA-
approvedagentisyttrium-90,aradioisotopethatemitshigh-
energy beta-particles, which was recently compared in a
small phase-I study with FOLFOX for unresectable CRLM
[89]. A radiographic partial response was observed in 90%
(18/20) of patients and stable disease in 10% (2/20), with a
progression-free survival of 9.3 months [89]. As with TAE
andTACE,alackofhigh-qualitydataexists,asevidencedbya
recentCochranereview[90]thatincludedonlyonerandom-
izedstudy:vanHazeletal.[91]comparedIARTplussystemic
chemotherapy and systemic chemotherapy alone and found
signiﬁcantlylongerprogression-freesurvivalfollowingIART.
As with TACE and TAE, more data are needed to improve
decision-making in patients with advanced CRLM.International Journal of Surgical Oncology 5
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
p
1000
900
800
700
600
500
400
300
200
100
0
Total number of laparoscopic liver resections
(a)
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
p
600
500
400
300
200
100
0
Benign
Benign versus malignant lesions
Malignant
(b)
Figure 2: Increase in reported MILRs over time (2002–2008
(partial)). Reproduced from Nguyen et al. Annals of Surgery 2009;
250:831 [92].
4. Comparison of OLR and MILR for CRLM
4.1. Oncologic Outcomes. The treatment of choice for CRLM
is surgical resection. As minimally invasive techniques, sur-
geon familiarity with those techniques, and minimally
invasive instruments—particularly coagulation and stapling
devices—have improved, the number of patients undergoing
MILR has increased exponentially in the recent years (Figure
2 [92]). Although early series reported resections that were
typically minor and performed for benign disease [93], in-
creased experience has lead to more aggressive MILR includ-
ingmalignantlesionsandmajorhepaticresections.Earlycri-
ticism of MILR was aimed at feared inability to maintain on-
cologic integrity. Indeed, similar concerns were weighed
against laparoscopic colon resection until randomized trials
supported equivalent safety, negative-margins status, and
disease-free survival [94, 95]. A large and growing global
experience (but no randomized controlled trials) suggests
that laparoscopic resection is safe and eﬀective for the man-
agement of liver lesions while maintaining oncologic integ-
rity [64, 65, 92].
In the absence of randomized controlled trials compar-
ing MILR with OLR, several observational studies have com-
pared these modalities, including cohort studies, case-con-
trolled studies, and intention-to-treat studies [96–103]; al-
thoughtheyshowsimilarratesofcomplicationsandsurvival,
many of these contain mixed patient populations including
benign and various malignant histologies. Nguyen and col-
leaguesreviewedalllaparoscopicresectionsperformedexclu-
sively for CRLM from 2000 to 2008. They identiﬁed 109 cas-
es, 97% of which were completed laparoscopically with a
94% negative-margin rate [104]. Forty-ﬁve percent of pa-
tients underwent a major (≥3 segments) hepatectomy, with
no mortalities and a 12% complication rate; actuarial sur-
vivalat1,3,and5yearswas88%,69%,and50%,respectively
[104], although no comparison to an open cohort was made.
Castaing et al. compared matched cases of laparoscopic
and open hepatectomy performed for CRLM and reported
comparable 5-year survival rates of 64% and 56% for laparo-
scopic and open LR, respectively [105], thus supporting
comparable oncologic outcomes. While the majority of the
laparoscopic resections reported in the literature are minor
(<3 segments), Dagher and colleagues studied a series of
210 major hepatectomies from 5 institutions, with 114 for
malignant disease [106], reporting a mortality of 1% (non-
liver-related) and an overall morbidity of 22% (8.1% liver-
related: 6.2% bile leak, 1.4% ascites, and 0.5% hemorrhage).
Positive margins were identiﬁed in only 3 patients (2.6%)
[106], which compares favorably to the rate of margin
positivity in OLR for CRLM which has had a wide variance
f r o m5t o2 4 %[ 107–109].
4.2. Caveats. Although margin status and oncologic out-
comes appear favorable these results should be interpreted
with caution, since selection bias is inherent in nonrandom-
ized studies and patients deemed laparoscopic candidates
may represent a diﬀerent and more favorable group. In the
Castaing series, for instance, the operative details are vari-
able, with vascular clamping occurring in 92% of the open
versus 17% in the laparoscopic group [105]. An interesting
study performed by Welsh et al. reviewed all patients who
underwent OLR for CRLM and divided them into 2 groups,
one suitable for MILR and another deemed best candidates
for OLR. Even though all resections were done open, those
identiﬁed as MILR candidates had a lower positive-margin
rate (4.5% versus 15%) and better 5-year survival (44%
versus 37%) [110].
Randomized data comparing MILR and OLR are, unfor-
tunately, unlikely to be obtained because of diﬃculty in de-
ﬁning end points (safety versus cost versus eﬃcacy), none of
which were deemed good end points for such a trial in
the recent international consensus Louisville Statement [64],
because of heterogeneity of the patient population and be-
cause of the length of time needed to accumulate enough
patients. The Louisville Statement did support a prospective
registry with preoperative enrollment, the creation of which
would help track the dissemination of procedures aimed at
improving patient safety [64]. Although initial nonrandom-
ized data suggest that MILR is likely a safe, oncologically6 International Journal of Surgical Oncology
sound means of managing CRLM, ongoing critical review,
multidisciplinaryteamsandparticipationinprospectivedata
collection or trials will continue to deﬁne optimal approach
to CRLM.
4.3. Cost and LOS. Examination of cost has been reported by
several groups in retrospective series. In a subgroup analysis
from the University of Louisville, Buell et al. retrospectively
reviewed and compared 29 laparoscopic and 34 open resec-
tions, ﬁnding signiﬁcant actual cost savings for a laparo-
scopicapproachtomajorresections($21,131versus$36,821;
P<0.0 1 )b e f o r e ,b u tn o ta f t e r ,a d j u s t m e n tf o rc h a n g e si n
Diagnosis-Related Group coding ($25,457 versus $23,691;
P<0.2) [111]. In a retrospective comparison of open ver-
sus laparoscopic left lateral segmentectomy, Vanounou et al.
at the University of Pittsburgh used deviation-based cost
modeling to analyze open and laparoscopic liver resections
(for both benign and malignant diseases) and found that the
overall LOS was 2 days shorter for the laparoscopic cases,
which was associated with a per-patient cost reduction of
$2939 compared to open cases [112]; when only malignant
cases were considered, however, that cost reduction was at-
tenuated at $1527 per patient.
Although both the Louisville and the Pittsburgh studies
showed signiﬁcantly shorter LOS for MILR versus OLR,
other data, derived from comparing standard recovery path-
wayversusafast-trackrecoverypathwayfollowingOLR,have
found a similar reduction in LOS (2 days) following fast-
track recovery [113]. Indeed, it has been argued [110, 114,
115]thatLOSisdeterminedmorebyextentofresectionthan
by operative approach and may be as little as 2–4 days with
either laparoscopic or open approach.
5. FutureDirectionsandControversies
5.1. Training and Credentialing. Broad surgical experience,
corroborated by many studies [116–118], demonstrates the
learning curve for MILR. Simillis et al., for instance, showed
that only in studies published after 2003 and in studies in-
cluding ≥20 laparoscopic proceduresdid theoperative blood
loss, LOS, and complications decrease for laparoscopic liver
s u r g e r yw h e nc o m p a r e dt oo p e nL R[ 117]. As the number of
MILR cases performed increases worldwide at a tremendous
rate(Figure 2[92])andastheMILRcommunityincreasingly
recognizes the infeasibility of performing randomized trials
ofMILR[64],therehavebeenmanycallsforaninternational
registry[64,92]ofMILRtomaintainarecordformonitoring
outcomes of eﬃcacy and patient safety, as has already been
achieved for natural oriﬁce transluminal endoscopic surgery
[119], an experimental modality much more widely used for
cholecystectomy (85% of all NOTES procedures) [119] than
for MILR [120, 121].
Training and credentialing of MILR are currently per-
formed at the local level and left to individual institutions.
At a minimum a strong combined expertise in major lapar-
oscopic surgery and advanced hepatobiliary techniques, inc-
luding knowledge and skill in the use of intraoperative
ultrasound, is required of a surgeon who wishes to begin
the learning curve for MILR [64, 117]. Currently, however,
there are no clear, widely accepted criteria that deﬁne this
required expertise [64]. A certiﬁcation process for MILR has
also yet to be deﬁned and the American Hepato-Pancreato-
BiliaryAssociationdoesnotcurrentlyrequireaspeciﬁcnum-
ber of MILR cases for the training of hepatobiliary surgeons
[122]. Many surgeons, however, recognize the need for a sys-
tematic progression frombasic to advanced laparoscopic and
hepatobiliary skills then to combined advanced laparoscopic
and hepatobiliary skills, and some have published their ex-
perience with starting an MILR program from scratch [123].
5.2. Learning Curve Eﬀect.
(1) The learning-curve eﬀect has not been studied exten-
sively in laparoscopic liver surgery. Numerous single-
institutionserieshaveshownanimprovementinout-
comes when the latter experience is compared to the
early experience [124, 125]. The ﬁrst detailed analysis
evaluating the learning curve eﬀect in MILR was
published by Vigano et al. in 2009, revealing signif-
icantly improved operative time, conversion rate,
blood loss, morbidity, and hospital stay progressive-
ly over time as experience and volume increased, de-
spite an increase in operative complexity over time
[126]. The shape of the learning curve was, not sur-
prisingly, similar to those reported regarding laparo-
scopic colectomy [127]. These results suggest that
MILR is reproducible in selected high-volume cen-
ters, by surgeons with advanced laparoscopic and he-
patobiliary training.
5.3. Combined Liver and Lung Metastases.
(1) Although the liver is the most common site of col-
orectal metastasis [3], another 3.5% of patients with
colon—and 11.5% of patients with rectal—cancer
will develop lung metastasis [128], most of whom
have both liver and lung diseases. Although early
(prior to 2001) studies of curative-intent metasta-
sectomy in patients with combined hepatic and pul-
monary colorectal metastases found widely variable
5-yearsurvivalrates,rangingfrom11%to44%[129–
132], more recent retrospective studies have pro-
duced improved 5-year survival rates as high as 64%
[133–137] in patients with colorectal pulmonary me-
tastases. Although fewer data are available regard-
ing minimally invasive treatment of pulmonary—
as compared to hepatic—colorectal metastases, large
recent series have shown that pulmonary metastasec-
tomies may be performed with minimally invasive
video-assisted thoracic surgery [137]. Another, even
less invasive option is RFA of pulmonary metastases.
Yamakadoetal.recentlystudiedaseriesof78patients
with 198 colorectal lung metastases treated with RFA,
reporting a 5-year and median survival of 35% and
38 months, respectively [138].International Journal of Surgical Oncology 7
5.4. Combined Liver and Peritoneal Metastases.
(1) Large series of patients with CRC have revealed that
4% to 19% of patients have colorectal carcinomatosis
at the time of the CRC resection or in follow up, al-
though as many as 80% of patients who die of CRC
have developed carcinomatosis by the time of their
death [139, 140]. In a review of nearly 3000 cases of
CRC in Singapore, 349 (13%) had carcinomatosis,
61% (214) of whom had disease that was synchro-
nous—and 39% (135) metachronous—with their in-
itial presentation of CRC [139]. The proportions
of CRLM patients with no carcinomatosis, with
metachronous carcinomatosis, and with synchro-
nous carcinomatosis were 10%, 33%, and 42%, res-
pectively, respectively [139]. An increasing body of
data [141], including randomized controlled data
[142], suggests that complete surgical eradication
of metastatic peritoneal disease with cytoreduction
and hyperthermic intraperitoneal chemotherapy
(HIPEC) is beneﬁcial to selected patients with colon
cancerwithcarcinomatosis,with5-yearsurvivalrates
>50% recently reported [143].
Although the presence of CRLM is often considered a
contraindication to cytoreduction and HIPEC, and similar-
ly the presence of carcinomatosis a contraindication to LR,
several recent studies [144–147] have evaluated the com-
bination of cytoreduction, HIPEC, and liver resection as an
aggressive emerging option for highly selected CRC patients
with both CRLM and peritoneal carcinomatosis. Elias et al.
[147] evaluated a series of 24 such patients with a mean Per-
itoneal Cancer Index (PCI) [148] of 8.6 (range: 2–25), half
of whom underwent a major hepatectomy, and reported
one postoperative death, a morbidity of 58%, and an over-
all 2-year survival of 61%. Patients with ≥3C R L Mh a ds i g -
niﬁcantly worse survival compared with patientS who had
<3C R L M[ 147]. More recently Chua et al. [144]e v a l -
uated a series of 16 patients with both CRLM and carci-
nomatosis treated by combined cytoreduction, HIPEC, and
liver resection and reported a 2-year survival of 65%; nei-
ther survival nor perioperative factors such as morbidity and
LOS were diﬀerent compared with patients who had isolated
carcinomatosis without CRLM, although those with both
CRLM and carcinomatosis had signiﬁcantly lower PCI
compared with patients with isolated carcinomatosis [144].
Most patients with CRLM and peritoneal carcinomatosis are
not, however, currently candidates for aggressive surgical re-
section of their CRLM and these emerging data should be
interpreted with caution.
Minimallyinvasivetechniqueshavebeenusedtoperform
cytoreduction to palliate metastatic disease to the ovaries
[149], to completely remove primary ovarian carcinomas
with limited peritoneal dissemination [150], and to do
staged laparoscopic HIPEC following open cytoreduction
[151]. The results of an ongoing protocol on laparoscopic
cytoreduction and HIPEC in patients with limited peritoneal
dissemination appear promising and compare favorably to
thosepatientshavinganopencytoreductiveprocedure[152],
suggesting that combining MILR and minimally invasive cy-
toreduction and HIPEC is on the horizon.
6. Summary
The number of cases of MILR performed in the world has
increased exponentially in recent years, and many centers are
nowperformingmajor,complexresections.Intheabsenceof
randomized trials comparing OLR and MILR, which is not
likely obtainable, nonrandomized data suggest that MILR
produces similar or improved morbidity, mortality, LOS,
and cost compared with OLR, although signiﬁcant selection
bias exists. Because randomized data will be diﬃcult or im-
possible to obtain, patient registries should be used to track
safety and eﬃcacy outcomes. Training of surgeons similarly
should become more formalized, including an independent
process for surgeon credentialing.
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